Efficacy of Vedolizumab for Inflammatory Bowel Disease in the Setting of DiGeorge Syndrome

被引：2
|
作者：
Thau, Eve [1 ]
Moore, Hillary Aaron [1 ]
Stein, Philip [1 ]
Chen, Kathy [1 ]
机构：
[1] Drexel Univ, St Christophers Hosp Children, Coll Med, Dept Pediat,Sect Gastroenterol Hepatol & Nutr, Philadelphia, PA 19104 USA
来源：
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION | 2019年 / 68卷 / 05期
关键词：
MAINTENANCE THERAPY; INDUCTION;
D O I：
10.1097/MPG.0000000000002322
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：E88 / E88
页数：1
相关论文
共 50 条
  • [31] VEDOLIZUMAB RELATED INFUSION REACTIONS IN INFLAMMATORY BOWEL DISEASE PATIENTS TREATED IN AN ALTERNATE CARE SETTING
    Checkley, Allyson
    Kristofek, Loretta
    Bolgar, William
    INFLAMMATORY BOWEL DISEASES, 2019, 25 : S31 - S31
  • [32] VEDOLIZUMAB RELATED INFUSION REACTIONS IN INFLAMMATORY BOWEL DISEASE PATIENTS TREATED IN AN ALTERNATE CARE SETTING
    Checkley, Allyson
    Kristofek, Loretta
    Bolgar, William
    GASTROENTEROLOGY, 2019, 156 (03) : S44 - S45
  • [33] Influence of disease location on vedolizumab efficacy in inflammatory bowel disease: a real-life multicentre experience
    Pestour, S.
    Nancey, S.
    Charlois, A. L.
    Bonaz, B.
    Flourie, B.
    Boschetti, G.
    Mathieu, N.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S65 - S66
  • [34] Effect of obesity on vedolizumab response in inflammatory bowel disease
    Levine, Louis
    Gaidos, Jill K. J.
    Proctor, Deborah D.
    Viana, Artur V.
    Al-Bawardy, Badr
    ANNALS OF GASTROENTEROLOGY, 2022, 35 (03): : 275 - 280
  • [35] SAFETY OF VEDOLIZUMAB USE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    Shivashankar, Raina
    Ladd, Antonio H. Mendoza
    Grace, Rory
    Aberra, Faten
    Lichtenstein, Gary R.
    GASTROENTEROLOGY, 2017, 152 (05) : S585 - S585
  • [36] Correction to: Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease
    Jurij Hanzel
    Christopher Ma
    Niels Vande Casteele
    Reena Khanna
    Vipul Jairath
    Brian G. Feagan
    Drugs, 2021, 81 : 1697 - 1697
  • [37] EFFECTS OF VEDOLIZUMAB ON EXTRAINTESTINAL MANIFESTATIONS IN INFLAMMATORY BOWEL DISEASE
    Dimopoulos, Christina
    Hung, Kenneth
    Proctor, Deborah
    Ruggiero, Eilzabeth
    Al-Bawardy, Badr
    GASTROENTEROLOGY, 2020, 158 (03) : S32 - S33
  • [38] EFFECTS OF VEDOLIZUMAB ON EXTRAINTESTINAL MANIFESTATIONS IN INFLAMMATORY BOWEL DISEASE
    Dimopoulos, Christina
    Hung, Kenneth
    Proctor, Deborah
    Ruggiero, Eilzabeth
    Al-Bawardy, Badr
    INFLAMMATORY BOWEL DISEASES, 2020, 26 : S19 - S20
  • [39] Vedolizumab in the induction and maintenance of inflammatory bowel disease treatment
    Tebar Marquez, D.
    REVISTA CLINICA ESPANOLA, 2014, 214 (03): : 161 - 162
  • [40] Ustekinumab and vedolizumab for extraintestinal manifestations in inflammatory bowel disease
    Livne-Margolin, M.
    Ling, D.
    Konyo, S. Attia
    Haj, O.
    Abitbol, C. M.
    Ben-Horin, S.
    Kopylov, U.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I429 - I430
12345